Taipei, Taiwan, January 24, 2024 – Merck, a leading science and technology company, has signed a Memorandum of Understanding (MoU) with Mycenax Biotech to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The agreement includes the integration of Merck’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.

"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck. “By combining the strengths of Merck and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”

As part of the agreement, Merck will offer Mycenax extensive support including consultation, technical assistance, and training, ensuring stakeholders receive expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.

"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with Merck aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."

For full release please visit www.mycenax.com.tw